Burks T F, Galligan J J, Porreca F
J Clin Gastroenterol. 1983;5 Suppl 1:29-36. doi: 10.1097/00004836-198312001-00004.
Drug receptors consist of recognition sites coupled to transducer and cellular amplifier mechanisms. Slight differences in receptor recognition sites can be exploited pharmacologically to provide drugs with a high degree of selectivity for activating or blocking individual receptor subtypes. For example, it may now be possible to block, selectively, subtypes of muscarinic cholinergic receptors in the gastrointestinal tract with pirenzepine and other drugs that discriminate between subtypes of muscarinic cholinergic receptors. The recognition of subtypes of adrenergic receptors may allow highly selective pharmacological activation and blockage of gastrointestinal neural and smooth muscle receptors. The development of nonpeptide receptor antagonists of gastrointestinal hormones and peptide neurotransmitters also offers promise for improved therapy of digestive diseases. Tremendous progress has occurred in recent years in defining multiple types of opioid receptors that alter gastrointestinal secretory, absorptive and motility functions. These receptors are located in the mucosa, nerves and muscle of the intestine and in the brain and spinal cord.
药物受体由与转导器和细胞放大机制相连的识别位点组成。受体识别位点的细微差异可被药理学利用,从而使药物对激活或阻断单个受体亚型具有高度选择性。例如,现在有可能用哌仑西平和其他能区分毒蕈碱型胆碱能受体亚型的药物,选择性地阻断胃肠道中的毒蕈碱型胆碱能受体亚型。对肾上腺素能受体亚型的识别,可能使胃肠道神经和平滑肌受体实现高度选择性的药理学激活和阻断。胃肠道激素和肽类神经递质的非肽类受体拮抗剂的研发,也为改善消化系统疾病的治疗带来了希望。近年来,在确定多种改变胃肠道分泌、吸收和运动功能的阿片受体方面取得了巨大进展。这些受体位于肠道的黏膜、神经和肌肉以及脑和脊髓中。